CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vaccinex Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vaccinex Inc
1895 Mount Hope Ave
Phone: (585) 271-2700p:585 271-2700 ROCHESTER, NY  14620-4540  United States Ticker: VCNXVCNX
This company ceased filing statements with the SEC on 3/27/2025.
Business Summary
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including neuroinflammatory and neurodegenerative diseases and cancer. It also discovered VX5 using its ActivMAb platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of autoimmune disorders.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Albert D.Friedberg 76 4/1/2001 4/1/2001
President, Chief Executive Officer, Director MauriceZauderer 77 4/1/2001 4/1/2001
Interim Chief Financial Officer JillSanchez 52 3/14/2024 3/14/2024
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Vaccinex Products, LP
VCNX

General Information
Number of Employees: 23 (As of 12/31/2024)
Outstanding Shares: 2,676,637 (As of 4/11/2025)
Shareholders: 146
Stock Exchange: OTC
Federal Tax Id: 161603202
Fax Number: (585) 271-2765


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, June 5, 2025